



## Emerging Company and Venture Capital

WilmerHale’s recognized Emerging Company and Venture Capital Practice has helped thousands of entrepreneurs successfully launch their businesses, raise billions in financing, and lead their companies to exits such as sales or IPOs and has supported leading VC firms in their investments for decades. Our clients depend upon our solution-focused, strategic advice and indispensable business perspective, and our team-oriented approach gives them the flexibility to call on our experts any time, including our more than 100 dedicated corporate lawyers located in key startup hubs.

### PRACTICE AT A GLANCE

- We work with founders to set up their companies; license core technology from universities, academic medical centers, and other institutions; obtain funding to propel their businesses forward; negotiate key agreements with management, employees, consultants, and advisors; and design equity incentive plans. As trusted advisors, we counsel clients throughout their life cycles, from incubating and scaling high-growth businesses to navigating strategic transactions and liquidity events.
- Our extensive experience with emerging companies allows us to efficiently manage venture capital financings and effectively navigate more complex transactions on behalf of investors. We have represented venture capital clients for more than five decades and assisted some of the earliest VC firms in their initial investments. We continue to represent many premier VC funds and corporate VCs.
- Leveraging the experience of our lawyers across offices—including in startup hubs such as Boston, Denver, New York, San Francisco, Silicon Valley, Washington DC, Berlin and Frankfurt—we serve startup and VC clients throughout the U.S. and across the globe.
- Our corporate capabilities are bolstered by our deep expertise across a variety of practice areas, including intellectual property, licensing, employment, tax, litigation, and regulatory matters.
- Our [WilmerHale Launch](#) website provides insights to investors and entrepreneurs at all stages of growth.
- WilmerHale’s QuickLaunch Program gives qualified startups the critical legal guidance they need to launch and build a competitive advantage. QuickLaunch members benefit from WilmerHale’s incorporation expertise and counseling at deferred, fixed and/or discounted rates.

**2,500+**

venture financings with total proceeds in excess of \$75 billion over the past decade

**\$7.5B**

raised in more than 170 venture financings in 2024



**Named *Law360*’s Technology Practice Group of the Year in 2016–2018 and 2022**

**Named *LMG Life Sciences*’ U.S. Life Cycle Firm in 2017–2025 and Venture Capital Firm of the Year in 2023**

## SELECT RECENT EMERGING COMPANY EXPERIENCE

- **BandLab** – a social music platform designed to create and share content with musicians and fans, in its \$53 million Series B financing
- **Clutch** – a FinTech company that partners with credit unions to modernize their operations, in its \$65 million Series B financing
- **Dedrone** – an automated drone security platform, in a \$60 million later-stage financing
- **Fervo Energy** – a provider of clean energy technology, in its \$138 million Series C financing
- **Flare Therapeutics** – a developer of medicines designed for precision oncology, in its \$123 million Series B financing
- **Flo Health** – the developer of the most downloaded women’s health app worldwide, in its \$200+ million Series C financing
- **Gameto** – a biotechnology company advancing treatment options in women’s health, in its \$33 million Series B financing
- **Georgiamune** – a biotechnology company developing next generation immunotherapy treatments for cancer and autoimmune diseases, in its \$75 million Series A financing
- **GiveCampus** – a social fundraising platform designed to help non-profit educational institutions, in its \$50 million Series A financing
- **HawkEye** – a commercial provider of space-based radio frequency data and analytics, in its \$68 million Series D financing
- **Immuta** – an AI data management software developer, in a \$90 million later stage financing
- **Introhive** – one of the fastest-growing AI-powered sales and revenue acceleration platforms, in its \$100 million Series C financing
- **Orna Therapeutics** – a biotechnology company pioneering engineered circular therapies, in its \$221 million Series B financing
- **Righthand Robotics** – a developer of supply chain logistics equipment, in its \$66 million Series C financing
- **Seaport Therapeutics** – a clinical-stage biopharmaceutical company advancing novel neuropsychiatric medicines, in its \$100 million Series A financing
- **Sierra Space** – a commercial space company building the first end-to-end business and technology platform in space, in its \$290 million Series B financing
- **Tractian** – a leader in manufacturing AI, in its \$120 million Series C financing
- **Volastra Therapeutics** – a biotechnology company focused on exploiting chromosomal instability (CIN), in its \$60 million Series A financing
- Represent investors such as **Bessemer Venture Partners, Casdin Capital, General Catalyst, Khosla Ventures, Pear Ventures, RA Capital, Samsara BioCapital, Spark Capital, and Wellington Management** in venture financings

For more information, please contact:

**Avery Reaves** — Co-Chair | +1 617 526 6657 | [avery.reaves@wilmerhale.com](mailto:avery.reaves@wilmerhale.com)

**Daniel Zimmermann** — Co-Chair | +1 650 858 6034 | [daniel.zimmermann@wilmerhale.com](mailto:daniel.zimmermann@wilmerhale.com)

## RECOGNITION

- Recognized as a top firm for Startups & Emerging Companies – **Chambers USA** (2017-2025)
- Recommended for Venture Capital and Emerging Companies – **The Legal 500 United States** (2010-2025)
- Ranked in the first tier nationally for Venture Capital Law – **U.S. News - Best Lawyers**® (2025)

We represent entrepreneurs and investors across a wide range of emerging industries, including:

